Zymeworks Inc (Zymeworks) is a clinical-stage biopharmaceutical company that discovers, develops and commercializes biotherapeutics for the treatment of cancer, autoimmune and inflammatory diseases. The company's lead product candidates are Zanidatamab for the treatment of biliary tract cancers, breast cancer, gastroesophageal adenocarcinomas and colorectal cancer, Zanidatamab Zovodotin for HER2-expressing cancers. Its other preclinical pipeline includes ZW191 - TOPO1i antibody-drug conjugate for ovarian and gynecological cancers and ZW171 for solid tumors. Zymeworks technology platform comprises Azymetric, Zymelink, Efect and Protect. It operates in the US and Canada. Zymeworks is headquartered in Vancouver, British Columbia, Canada.
Zymeworks Inc premium industry data and analytics
Products and Services
Products | Brands |
---|---|
Pipeline | Zymeworks |
Zanidatamab (Biliary Tract Cancers, Breast Cancer, Gastroesophageal Adenocarcinomas and Colorectal Cancer) | ProTECT |
Zanidatamab Zovodotin (HER2-Expressing Cancers) | EFECT |
XYZ | |
XYZ | |
XYZ |
Competitor Comparison
Key Parameters | Zymeworks Inc | Seagen Inc | Puma Biotechnology Inc | MacroGenics Inc | AngioChem Inc |
---|---|---|---|---|---|
Headquarters | United States of America | United States of America | United States of America | United States of America | Canada |
City | Middletown | Bothell | Los Angeles | Rockville | Westmount |
State/Province | Delaware | Washington | California | Maryland | Quebec |
No. of Employees | 272 | 3,256 | 185 | 339 | - |
Entity Type | Public | Private | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Kenneth Galbraith | Chairman; Chief Executive Officer | Executive Board | 2022 | 60 |
Christopher Astle | Senior Vice President; Chief Financial Officer | Senior Management | 2021 | 43 |
Neil Klompas | President; Chief Operating Officer | Senior Management | 2017 | 51 |
Jeffrey Smith | Chief Medical Officer; Executive Vice President | Senior Management | 2024 | - |
Paul Moore | Chief Scientific Officer | Senior Management | 2022 | - |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer